Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

, MRK

Merck

$54.90

(0.00%)

07:33
02/15/18
02/15
07:33
02/15/18
07:33

Bristol-Myers upgraded on immuno-oncology growth prospects at Morgan Stanley

As previously reported, Morgan Stanley analyst David Risinger upgraded Bristol-Myers (BMY) to Overweight from Equal Weight as he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. After the analyst reviewed combo toxicity in select combo studies with similar dosing as Bristol's CM-227 and compared cross trial against Merck's (MRK) Keynote-021G trial that tested Keytruda + chemo, he concluded that discontinuation rates due to side effects appear roughly comparable and now thinks Opdivo + Yervoy toxicity in lung cancer is likely to be acceptable. Risinger raised his price target on Bristol-Myers shares to $78 from $63.

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

MRK

Merck

$54.90

(0.00%)

  • 15

    Feb

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Oct

BMY Bristol-Myers
$65.35

1.48 (2.32%)

02/14/18
MZHO
02/14/18
NO CHANGE
Target $89
MZHO
Buy
Nektar deal with Bristol-Myers could eventually lead to takeover, says Mizuho
After Nektar (NKTR) announced a new immune-oncology collaboration agreement with Bristol-Myers Squibb (BMY), Mizuho analyst Difei Yang said she believes the deal values Nektar at approximately $9B-$10B and may lead to an eventual takeout. She maintains her Buy rating and $89 price target on Nektar shares.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.
02/15/18
MSCO
02/15/18
UPGRADE
MSCO
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
02/15/18
SBSH
02/15/18
NO CHANGE
Target $62
SBSH
Neutral
Alkermes catalysts are the major focus this year, says Citi
Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.
MRK Merck
$54.90

(0.00%)

01/16/18
01/16/18
UPGRADE
Target $72

Buy
Merck upgraded on earlier than expected Keytruda trial success at SunTrust
As previously reported, SunTrust analyst John Boris upgraded Merck to Buy from Hold, stating that he had expected positive data from the Keynote-189 trial but that the positive results on Progression Free Survival and Overall Survival came earlier than expected. This timing should enable Merck to maintain its first-mover advantage in first-line non-squamous Non-Small Cell Lung Cancer, or NSCLC, in the U.S. and file in the EU, Boris tells investors. He raised his price target to $72 from $54 on Merck shares, which are up $4.09, or 7%, to $62.75 in morning trading.
01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.
02/14/18
BMOC
02/14/18
NO CHANGE
Target $65
BMOC
Outperform
Merck price target lowered to $65 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Merck to $65 after the company discontinued its APECS study. The analyst sees this as "another setback that increases Merck's dependence on Keytruda" and contends that the company needs other meaningful drivers. Arfaei keeps his Outperform rating based on his confidence in Keytruda growth and Merck's Immuno-oncology execution.
02/15/18
PIPR
02/15/18
NO CHANGE
Target $407
PIPR
Overweight
Biogen selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends using the selloff yesterday in shares of Biogen (BIIB) as a buying opportunity. The stock pulled back after management disclosed at a conference plans to up-size the Phase 3 aducanumab program by 510 patients total. While "this is a bit unnerving," particularly on the heels of another Phase 3 Alzheimer's failure for Merck's (MRK) verubecestat, the study remains blinded and variability on the primary endpoint can stem from a host of reasons, not all of them bad, Raymond tells investors in a research note titled "Aducanumab P3 Upsizing Doesn't Tell Us Much." The analyst does not think yesterday's news says much about the chances for an interim analysis or about aducanumab's efficacy profile. He keeps an Overweight rating on Biogen with a $407 price target.

TODAY'S FREE FLY STORIES

IIPR

Innovative Industrial Properties

$90.00

-0.175 (-0.19%)

13:09
03/23/19
03/23
13:09
03/23/19
13:09
Periodicals
Innovative Industrial Properties flying high, Barron's says »

American cannabis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$129.80

-4.1 (-3.06%)

13:05
03/23/19
03/23
13:05
03/23/19
13:05
Periodicals
Investors missing how far Caterpillar dug into costs, Barron's says »

Caterpillar has made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

MO

Altria Group

$55.90

-0.23 (-0.41%)

12:59
03/23/19
03/23
12:59
03/23/19
12:59
Periodicals
E-cigarettes not helping people quit smoking, Barron's says »

According to the CDC,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

MAN

Manpower

$80.83

-5.02 (-5.85%)

, SABR

Sabre

$21.02

-0.62 (-2.87%)

12:51
03/23/19
03/23
12:51
03/23/19
12:51
Periodicals
Sabre, j2 Global among mid-cap stocks with sustainable dividends, Barron's says »

When it comes to…

MAN

Manpower

$80.83

-5.02 (-5.85%)

SABR

Sabre

$21.02

-0.62 (-2.87%)

WBS

Webster Financial

$48.90

-3.03 (-5.83%)

NATI

National Instruments

$44.16

-1.28 (-2.82%)

JCOM

j2 Global

$84.63

-1.95 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 10

    May

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

, GME

GameStop

$10.57

0.03 (0.28%)

12:47
03/23/19
03/23
12:47
03/23/19
12:47
Periodicals
Gaming meets the cloud as investors scramble to catch up, Barron's says »

The cloud will eventually…

MSFT

Microsoft

$117.05

-3.6 (-2.98%)

GME

GameStop

$10.57

0.03 (0.28%)

AMD

AMD

$26.43

-1.47 (-5.27%)

SNE

Sony

$42.09

-1.915 (-4.35%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 02

    Apr

  • 04

    Apr

  • 16

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

LYFT

Lyft

$0.00

(0.00%)

12:42
03/23/19
03/23
12:42
03/23/19
12:42
Periodicals
Investors should avoid booking ride when Lyft goes public, Barron's says »

Lyft will soon be going…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DIS

Disney

$108.30

-0.36 (-0.33%)

, AAPL

Apple

$191.11

-3.96 (-2.03%)

12:38
03/23/19
03/23
12:38
03/23/19
12:38
Periodicals
Streaming revolution too complicated, Barron's says »

The streaming revolution…

DIS

Disney

$108.30

-0.36 (-0.33%)

AAPL

Apple

$191.11

-3.96 (-2.03%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$39.56

-0.49 (-1.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 11

    Apr

  • 25

    Apr

  • 08

    May

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

PLNT

Planet Fitness

$66.76

-0.825 (-1.22%)

18:44
03/22/19
03/22
18:44
03/22/19
18:44
Hot Stocks
Planet Fitness CEO: We have a streamlined business model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRDM

Iridium

$26.40

-0.38 (-1.42%)

18:22
03/22/19
03/22
18:22
03/22/19
18:22
Hot Stocks
Iridium CEO: We've doubled our bottom line over the past eight years »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:05
03/22/19
03/22
18:05
03/22/19
18:05
General news
Sen. Sanders calls on White House to make Mueller report public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

, RNECY

Renesas

$0.00

(0.00%)

18:02
03/22/19
03/22
18:02
03/22/19
18:02
Hot Stocks
Integrated Device, Renesas receive final approval for merger »

Renesas Electronics…

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

RNECY

Renesas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:48
03/22/19
03/22
17:48
03/22/19
17:48
General news
Senator Warren urges AG Barr to release Mueller report to the public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
Lawmaker urges FAA, Boeing workers to utilize whistleblower page »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

GLD

SPDR Gold Shares

$123.97

0.29 (0.23%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
SPDR Gold Shares holdings rise to 781.03MT from 778.09MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:40
03/22/19
03/22
17:40
03/22/19
17:40
General news
Weekly CFTC Commitment of Traders highlights »

10-YEAR U.S. TREASURY net…

ONEXF

Onex

$0.00

(0.00%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Onex to acquire Gluskin Sheff »

Onex Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

REPH

Recro Pharma

$9.73

0.1 (1.04%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Breaking Hot Stocks news story on Recro Pharma »

Recro Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Mar

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:34
03/22/19
03/22
17:34
03/22/19
17:34
General news
White House says hasn't received, been briefed on Mueller report, WSJ says »

Following confirmation…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATS

Catasys

$13.19

-0.39 (-2.87%)

17:26
03/22/19
03/22
17:26
03/22/19
17:26
Syndicate
Breaking Syndicate news story on Catasys »

Catasys files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USWS

U.S. Well Services

$7.74

-0.54 (-6.52%)

17:20
03/22/19
03/22
17:20
03/22/19
17:20
Syndicate
Breaking Syndicate news story on U.S. Well Services »

U.S. Well Services files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.